Non-Small Cell Lung Cancer Clinical Trials Analysis 2024: FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration , and Companies by DelveInsight

As per DelveInsight's assessment, globally, Non-Small Cell Lung Cancer pipeline constitutes 135+ key companies continuously working towards developing 145+ Non-Small Cell Lung Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Non-Small Cell Lung Cancer Pipeline Insight 2024 [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Small Cell Lung Cancer Market.

The Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Non-Small Cell Lung Cancer Pipeline Report:

* NSCLC Companies across the globe are diligently working toward developing novel Non-Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years.
* Non-Small Cell Lung Cancer companies working in the treatment market are J INTS BIO BIO CO.,LTD., Mirati Therapeutics, MediLink Therapeutics, BioNTech SE, Cellular Biomedicine Group, Shenzhen TargetRx, Inc., Iovance Biotherapeutics, Revolution Medicines, Inc., Genmab, Incyte Corporation, Daiichi Sankyo, Novartis, and others, are developing therapies for the Non-Small Cell Lung Cancer treatment.
* Emerging Non-Small Cell Lung Cancer therapies in the different phases of clinical trials are- JIN-A03, MRTX1133, YL202, BNT116, C-TIL051, TGRX-326, LN-145, RMC-4630, GEN1046, Retifanlimab, DS-1062a, JDQ443, and others are expected to have a significant impact on the Non-Small Cell Lung Cancer market in the coming years.
* In January 2023, According to Novocure, the primary endpoint of the LUNAR study, which assessed the safety and effectiveness of Tumor Treating Fields (TTFields) in combination with standard therapies for stage 4 non-small cell lung cancer (NSCLC) that progressed during or after platinum-based therapeutic treatment, was reached.
* In June 2023, At the 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023), Qilu Pharmaceutical presented trials in progress poster presentations on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immunotherapy, in two Phase III clinical studies of non-small cell lung carcinoma (NSCLC).
* In May 2023, The first patient in the United States has been enrolled in the Phase III HARMONi study, according to a statement released by Summit Therapeutics. Phase III multiregional, randomized, double-blinded research is called HARMONi. In patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) like osimertinib, the study will assess the safety and effectiveness of ivonescimab in combination with chemotherapy.
* In May 2023, Updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) without mutations in the anaplastic lymphoma kinase (ALK) or EGFR gene and PD-L1 tumor proportion score (TPS) of 50% were released by Gilead Sciences and Arcus Biosciences. The potential therapeutic effect of blocking the TIGIT path is supported by progression-free survival curves that demonstrated early separation of both domvanalimab-containing arms from the zimberelimab arm, which was persistently maintained.
* In December 2022, Mirati's Krazati (adagrasib), a targeted therapeutic option for adult patients with KRAS-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), received accelerated approval from the US FDA.
* In December 2022, In order to assess the efficacy and safety of JDQ443 single-agent as a first-line treatment for patients with a locally advanced or metastatic KRAS G12C mutation, Novartis Pharmaceuticals started an open-label Phase II trial.

Non-Small Cell Lung Cancer Overview

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and includes several subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. It typically develops in the epithelial cells lining the lungs and is strongly associated with smoking, although non-smokers can also develop NSCLC due to other factors like exposure to secondhand smoke, radon, or air pollution.

Symptoms of NSCLC may include persistent cough, chest pain, shortness of breath, coughing up blood, fatigue, and unintentional weight loss. Diagnosis involves imaging tests (CT scan, PET-CT scan) and biopsy confirmation to determine the subtype and molecular characteristics of the cancer.

Treatment options depend on the stage of the cancer and the patient's overall health. Early-stage NSCLC may be treated with surgery (lobectomy or segmentectomy) or stereotactic body radiation therapy (SBRT). Advanced NSCLC is typically managed with systemic therapies such as chemotherapy, targeted therapy (for tumors with specific genetic mutations like EGFR or ALK), and immunotherapy (checkpoint inhibitors like pembrolizumab or nivolumab).

Prognosis varies widely based on factors such as stage at diagnosis, subtype of NSCLC, genetic mutations, and response to treatment. Advances in personalized medicine and immunotherapy have improved outcomes for some patients with NSCLC, highlighting the importance of molecular testing and individualized treatment approaches.

Get a Free Sample PDF Report to know more about Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight [https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Emerging Non-Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:

* JIN-A03: J INTS BIO BIO CO.,LTD.
* MRTX1133: Mirati Therapeutics
* YL202: MediLink Therapeutics Co., Ltd.
* BNT116: BioNTech SE
* C-TIL051: Cellular Biomedicine Group
* TGRX-326: Shenzhen TargetRx, Inc.
* LN-145: Iovance Biotherapeutics
* RMC-4630: Revolution Medicines, Inc.
* GEN1046: Genmab
* Retifanlimab: Incyte Corporation
* DS-1062a: Daiichi Sankyo
* JDQ443: Novartis Pharmaceuticals

Non-Small Cell Lung Cancer Route of Administration

Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

* Intranasal
* Intrathecal
* Intravenous
* Oral
* Oral/Intravenous
* Parenteral
* Subcutaneous
* Subcutaneous/Intramuscular
* Transdermal

Non-Small Cell Lung Cancer Molecule Type

Non-Small Cell Lung Cancer Products have been categorized under various Molecule types, such as

* Antisense oligonucleotide
* Gene therapy
* Hormones
* Neuropeptides
* Oligonucleotides
* Small Molecule
* Triglyceride

Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

* Non-Small Cell Lung Cancer Assessment by Product Type
* Non-Small Cell Lung Cancer By Stage and Product Type
* Non-Small Cell Lung Cancer Assessment by Route of Administration
* Non-Small Cell Lung Cancer By Stage and Route of Administration
* Non-Small Cell Lung Cancer Assessment by Molecule Type
* Non-Small Cell Lung Cancer by Stage and Molecule Type

DelveInsight's Non-Small Cell Lung Cancer Report covers around 145+ products under different phases of clinical development like

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Further Non-Small Cell Lung Cancer product details are provided in the report. Download the Non-Small Cell Lung Cancer pipeline report to learn more about the emerging Non-Small Cell Lung Cancer therapies [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key companies in the Non-Small Cell Lung Cancer Therapeutics Market include:

Non-Small Cell Lung Cancer companies developing therapies are - GlaxoSmithKline, Pfizer, AstraZeneca, Seagen, MacroGenics, Roche, Summit Therapeutics, Arcus Biosciences, Qilu Pharmaceutical, Shandong New Age Pharmaceutical, Symphogen, and others.

Non-Small Cell Lung Cancer Pipeline Analysis:

The Non-Small Cell Lung Cancer pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Non-Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Small Cell Lung Cancer Treatment.
* Non-Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Non-Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Small Cell Lung Cancer market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Small Cell Lung Cancer drugs and therapies [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Non-Small Cell Lung Cancer Pipeline Market Drivers

Increasing prevalence of non small cell lung cancer, increasing launch of pipeline therapies are some of the important factors that are fueling the Non-Small Cell Lung Cancer Market.

Non-Small Cell Lung Cancer Pipeline Market Barriers

However, high cost of therapies entering the market, requirement of adequate reimbursement policies for NSCLC drugs and other factors are creating obstacles in the Non-Small Cell Lung Cancer Market growth.

Scope of Non-Small Cell Lung Cancer Pipeline Drug Insight

* Coverage: Global
* Key Non-Small Cell Lung Cancer Companies: J INTS BIO BIO CO.,LTD., Mirati Therapeutics, MediLink Therapeutics, BioNTech SE, Cellular Biomedicine Group, Shenzhen TargetRx, Inc., Iovance Biotherapeutics, Revolution Medicines, Inc., Genmab, Incyte Corporation, Daiichi Sankyo, Novartis, and others
* Key Non-Small Cell Lung Cancer Therapies: JIN-A03, MRTX1133, YL202, BNT116, C-TIL051, TGRX-326, LN-145, RMC-4630, GEN1046, Retifanlimab, DS-1062a, JDQ443, and others
* Non-Small Cell Lung Cancer Therapeutic Assessment: Non-Small Cell Lung Cancer current marketed and Non-Small Cell Lung Cancer emerging therapies
* Non-Small Cell Lung Cancer Market Dynamics: Non-Small Cell Lung Cancer market drivers and Non-Small Cell Lung Cancer market barriers

Request for Sample PDF Report for Non-Small Cell Lung Cancer Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Non-Small Cell Lung Cancer Report Introduction

2. Non-Small Cell Lung Cancer Executive Summary

3. Non-Small Cell Lung Cancer Overview

4. Non-Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment

5. Non-Small Cell Lung Cancer Pipeline Therapeutics

6. Non-Small Cell Lung Cancer Late Stage Products (Phase II/III)

7. Non-Small Cell Lung Cancer Mid Stage Products (Phase II)

8. Non-Small Cell Lung Cancer Early Stage Products (Phase I)

9. Non-Small Cell Lung Cancer Preclinical Stage Products

10. Non-Small Cell Lung Cancer Therapeutics Assessment

11. Non-Small Cell Lung Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non-Small Cell Lung Cancer Key Companies

14. Non-Small Cell Lung Cancer Key Products

15. Non-Small Cell Lung Cancer Unmet Needs

16 . Non-Small Cell Lung Cancer Market Drivers and Barriers

17. Non-Small Cell Lung Cancer Future Perspectives and Conclusion

18. Non-Small Cell Lung Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nonsmall-cell-lung-cancer-clinical-trials-analysis-2024-fda-approvals-pipeline-therapies-mechanism-of-action-route-of-administration-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting



This release was published on openPR.